De-scalation or swItch of Treatment According to Circulating tuMOr DNA Variation After 2 Cycles of Doublet Chemotherapy Plus Targeted Agent in Metastatic Unresectable Colorectal Cancer

NCT06446557 · clinicaltrials.gov ↗

PHASE3

Phase

NOT_YET_RECRUITING

Status

408

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Colon Cancer

Interventions

DRUG: treatment adaptation guided by ctDNA variation
DRUG: standard management

Sponsor

University Hospital, Rouen